Geron Corp

NASDAQ: GERN
$3.56
-$0.02 (-0.6%)
Closing price April 25, 2024
Geron Corp is a biopharmaceutical company focused on developing treatments for blood cancers. Its main project, imetelstat, is a groundbreaking therapy aimed at stopping the spread of cancerous cells in certain blood disorders. This innovative drug is currently in advanced testing stages, showing promise for patients with specific types of myelodysplastic syndromes and myelofibrosis. Founded in 1990 and based in Foster City, California, Geron is at the forefront of research in telomerase inhibition, a novel approach in cancer treatment.
Geron is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower on the day.
24/7 Wall Street has picked out a few companies posting the largest losses for the week, including Novavax and VimpelCom.
September 12, 2016: Here are four stocks trading with relatively heavy volume among 56 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by more than 2 to 1 and...
Investors never like to see a stock they own drop 17%, but there is at least one view that maybe the drop is an opportunity for those with longer-term views who remain bullish.
Biotech is the one arena that still offers massive upside for investors — if they can pick the right companies that is. They could one day cure cancer, heart issues, diabetes and just about every...
A research report from Janney's Roy Buchanan issued on Friday included a fair value estimate for Geron shares that was more than 100% above the share price of the time.
Friday's top analyst calls include Best Buy, 3D Systems, Electronic Arts, Gilead Sciences, Nokia, Shire and United Rentals.
Biotech gets a lot of sustained attention, but some stocks still fall through the cracks, either due to recent failures or general lack of interest.
On the close Tuesday, the PowerShares Dynamic exchange traded funds (ETFs) are set for a rebalance. These four stocks that are expected to have huge buying on the close Tuesday.
Geron hasannounced that it entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat.
The FDA gave Geron some good news Monday morning when it removed the clinical hold on the its investigational new drug application for imetelstat.
Source: bfishshadow via Wikimedia CommonsSince the beginning of the year, the Nasdaq Composite Index has given up more than 4% of its value, dropping from a high of around 4,357 in early March to...
Source: thinkstockMarch 18, 2014: Markets opened higher on Tuesday and the number buyers rose throughout the day. There was something of a Vladimir Putin rally today following Russia’s formal...
Source: thinkstockMarch 12, 2014: Markets opened lower on Wednesday following a so-so trading day in Europe. Crude oil pulled back 2% after the EIA’s inventory report indicated a larger inventory...
Geron is getting a reality check on Wednesday. After a recovery from years of disappointment, this is starting to feel again like the Geron that everyone knew before.